Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a major
component of the pathogenesis of many common neurodegenerative diseases known as proteinopathies. The
intermediate products of this aggregation are toxic to neurons and may be lethal. The development strategy of
pathogenic therapy for proteinopathy is based on the design of drugs capable of both inhibiting proteinopathy
progression and increasing the survival of affected neurons. The results of a decade-long research effort at
leading Russian and international laboratories have demonstrated that Dimebon (Latrepirdine), as well as a
number of its derivatives from a gamma-carboline group, show a strong neuroprotective effect and can modulate
the course of a neurodegenerative process in both in vitro and in vivo model systems. The accumulated
data indicate that gamma-carbolines are promising compounds for the development of pathogenic therapy for
proteinopathies